Aptinyx discovers and develops
innovative therapies for
challenging disorders of the brain and
nervous system.

nerve 650

Aptinyx's proprietary compounds modulate
the NMDA receptor,
a critical regulator
involved in nerve cell
communication.

Aptinyx seeks to leverage its experience and
track record of success to rapidly advance promising therapies in development for patients in need.

About Aptinyx

Aptinyx Inc. is a clinical-stage biopharmaceutical company focused on the discovery and development of transformative therapies for challenging neurologic disorders. Aptinyx has a proven platform for discovering compounds that work through a novel mechanism: modulation of NMDA receptors to enhance communication between neural cells.

Learn more about Aptinyx »

Latest News

March 30, 2020
Aptinyx Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

March 18, 2020
Aptinyx to Report Fourth Quarter and Full Year 2019 Financial Results on Monday, March 30, 2020

February 19, 2020
Aptinyx to Present at Upcoming Investor Conferences

January 30, 2020
Aptinyx Announces Publication of Data in Movement Disorders Demonstrating Reversal of Cognitive Deficits with NYX-458 in Primate Model of Parkinson’s Disease

January 14, 2020
Aptinyx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option

See all press and news »